ArticleScientific reports2026
Comparative analysis of sex-based, vendor-based, and species differences in cytochrome P450 metabolism.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of the antidepressant-like effects of ginsenosides in animal models: comparative behavioral profiles and exploratory dose-stratified analysis.Frontiers in pharmacology · 2026Pooled it
- Human internal exposures to alternariol and its monomethyl ether are predicted below thresholds of in vitro toxicity by physiologically based kinetic modeling.Archives of toxicology · 2026Article
- Tripterygium Glycosides Extract-Induced Hepatic Cholestasis: A Mechanistic Study Using a Microfluidic Liver-on-a-Chip System.International journal of molecular sciences · 2026Article
- Zebrafish as a translational filter for natural sleep modulators.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic clearance is crucial as it directly impacts drug exposure, efficacy, and safety. Cytochrome P450 (CYP450) enzymes play a pivotal role in drug metabolism and exhibit differences based on sex, species, and commercial liver microsome vendors. These variables can directly influence translational accuracy when preclinical data are applied to human drug development. In this study, we evaluated metabolic stability of isozyme-selective compounds across human, rat, and mouse liver microsomes, incorporating both male and female microsomes and multiple vendors. Our analysis revealed three layers of variability: (1) sex-specific differences consistent with prior clinical observations, where certain substrates displayed markedly faster clearance in one sex; (2) interspecies divergence, such as male-predominant isoforms in rodents without direct human orthologs; and (3) vendor-related discrepancies, where the same species-sex pool yielded divergent stability outcomes depending on microsome source. Together, these findings illustrate the combined effects of sex, species, and vendor source that contribute to variability in CYP450-mediated metabolism. By systematically comparing these factors, our work underscores the importance of considering these variables during early preclinical studies. Accounting for these sources of variability may improve the translational reliability of in vitro assays, reduce costly late-stage failures, and better support the development of safe and effective therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.